事業に関するお知らせ 日本再生医療学会YOKOHAMA 宣言2025について

再生医療等実用化基盤整備促進事業において日本再生医療ナショナルコンソーシアムを運営する日本再生医療学会からのプレスリリースを掲載いたします。

日本再生医療学会（JSRM）は、再生医療に対する国際的な懸念や指摘を真摯に受け止め、説明責任を果たすため、積極的に患者・市民および社会全体との対話を進めております。
この度、この取組を進めるため、第24回日本再生医療学会において、「YOKOHAMA宣言2025」を発表いたしました。

特に、薬機法に基づき承認された治療法に加え、再生医療等安全性確保法（安確法）下で自由診療として提供される医療技術に関して、「検証」を伴う「検証型診療」と、「検証」を伴わない「無検証診療」とを明確に区別し、それぞれの内容を透明性高く社会に提示します。

JSRMはこの取り組みを通じて、日本における再生医療の適正な普及と発展を促進し、国際的に通用する信頼性と倫理的基準を確立してまいります。

【お問い合わせ】
日本再生医療学会外務室：foreignaffairs”AT”jsrm.jp（”AT”を@に変更してください。）

Japanese Society for Regenerative Medicine Announces the YOKOHAMA Declaration 2025
—Committing to Scientific Rigor and Ethical Responsibility in Regenerative Medicine—

Tokyo, Japan —March 19, 2025— The Japanese Society for Regenerative Medicine (JSRM), Japan’s leading scientific organization dedicated to advancing regenerative medicine, today announced the adoption of the “YOKOHAMA Declaration 2025” during its 24th Annual Meeting, held in Yokohama, Japan.
In response to growing international concerns about the proliferation of unverified regenerative medicine practices provided under Japan’s Act on the Safety of Regenerative Medicine (ASRM), JSRM recognizes its responsibility to clearly differentiate scientifically valid treatments from those lacking sufficient scientific scrutiny.

The Declaration explicitly distinguishes:

1. Explorative Therapy:
   Therapy using processed cells or nucleic acids, etc. for which a manufacturing and marketing approval has not been obtained under PMD Act, and for which clinical data are accumulated in an independent third-party registry and an Explorative Study is conducted both prior to and following the treatment
2. Uninvestigated Therapy:
   Therapy not qualified as “Explorative Therapy,” by using processed cells or nucleic acids, etc. for which a manufacturing and marketing approval has not been obtained under PMD Act

Through this Declaration, JSRM commits to promoting active dialogue with patients, the general public, and medical professionals engaged in clinical practice, to enhance awareness and accurate understanding of approved treatments and explorative regenerative medical practices.

The Society further commits to developing practical guidelines that ensure transparency, patient protection, and scientific integrity within the field of regenerative medicine in Japan.

Media Contact:
Jun Takiyama, Head of Foreign Affairs
Email: foreignaffairs”AT”jsrm.jp (Replace "AT" with @)